Targeting leptin signaling by using the peptide LDFI, or blocking JAK2/STAT3 signaling completely abrogated these effects, suggesting that the possibility that pharmacologically blocking leptin signaling might attenuate Notch activity in GBM. Here, JAK2 is linked to glioblastoma.